US20210254181A1 - Multi-copy reference assay - Google Patents

Multi-copy reference assay Download PDF

Info

Publication number
US20210254181A1
US20210254181A1 US17/301,976 US202117301976A US2021254181A1 US 20210254181 A1 US20210254181 A1 US 20210254181A1 US 202117301976 A US202117301976 A US 202117301976A US 2021254181 A1 US2021254181 A1 US 2021254181A1
Authority
US
United States
Prior art keywords
sequence
interest
chr1
reference sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/301,976
Inventor
David Merrill
Pius Brzoska
Zheng Li
Wendy Lin
Wing Lee
Mandi WONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Technologies Corp
Original Assignee
Life Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Technologies Corp filed Critical Life Technologies Corp
Priority to US17/301,976 priority Critical patent/US20210254181A1/en
Assigned to Life Technologies Corporation reassignment Life Technologies Corporation ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRZOSKA, PIUS, WONG, Mandi, LEE, WING, MERRILL, DAVID, LIN, WENDY, LI, ZHENG
Publication of US20210254181A1 publication Critical patent/US20210254181A1/en
Priority to US18/635,799 priority patent/US20240263247A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes

Definitions

  • Information relating to the copy number of a target of interest in the genome of a biological sample may be desirable for a number of purposes, including basic research and clinical diagnosis of various diseases.
  • One class of diseases where the copy number of a target of interest may be particularly desirable to know is cancer.
  • Numerous cancers present with abnormal copy numbers of one or more genes. In many cases, there exists a positive correlation between copy number and the existence and/or progression of cancer. Therefore, determining the copy number of a target of interest in a sample from a patient of tissue suspected of being cancer tissue may be useful, for example, in diagnosing, treating, and/or monitoring the course of the patient's cancer.
  • qPCR quantitative polymerase chain reaction
  • the technique when attempting to apply qPCR to determine the copy number of a target of interest in a cancer cell, the technique may be rendered difficult as a result of one or both of the random, evolving genomic abnormalities (e.g., aneuploidy) found in cancer cells and the modifications to nucleic acids that may occur when tissue samples are archived by formalin fixing and paraffin embedding (FFPE).
  • FFPE formalin fixing and paraffin embedding
  • Genomic abnormalities of various types are known to occur in cancer cells, and increase in their quantity, distribution, and complexity as the cancer cells are replicated over time. These genomic abnormalities include gene deletions and multiplications, some of which may be related to a specific function in humans and common to certain cancer types, while others may have no overt effect or association with disease. As a result, a reference sequence of interest may undergo deletion and/or multiplication in the genome of a cancer cell, thereby making it very difficult to determine the absolute copy number of the reference sequence.
  • nucleic acids DNA and RNA
  • cross linking of nucleotides to themselves or proteins, depurination of nucleotides, and fragmentation of the nucleic acids are known to occur as part of the archiving of cancer samples by the FFPE method.
  • the locations and extent of these modifications are random and vary greatly across FFPE samples, due in large part to one or more factors, such as variability in the sample tissue itself, reagents used in fixation and embedding, and user preferred variations in the FFPE method at different labs. These effects also make it difficult or impossible to determine the absolute copy number of the reference sequence.
  • the present disclosure relates to a method, comprising quantifying a nucleic acid sequence of interest relative to a reference nucleic acid sequence, wherein at least a first minimum number of copies of the reference nucleic acid sequence is present on each of at least a second minimum number of chromosomes of the genomic DNA of the subject; and determining a copy number of the sequence of interest from the relative quantified amplified sequence of interest.
  • the method may further comprise amplifying the nucleic acid sequence of interest in a sample comprising genomic DNA of a subject; and amplifying the reference nucleic acid sequence in the sample; prior to quantifying.
  • the reference sequence may have at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, chr5-180756063-180768074, chr6-1709
  • the reference nucleic acid sequence may have at least 80% sequence identity to at least one of
  • the present disclosure relates to a kit, comprising a first probe which specifically hybridizes to at least a portion of at least one reference sequence that has at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4
  • the present disclosure relates to a composition, comprising a first probe which specifically hybridizes to at least a portion of at least one reference sequence that has at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chrl-222643865-228172047, chrl-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chrr
  • the present disclosure relates to a system, comprising a nucleic acid amplifier configured to amplify a nucleic acid sequence of interest in a sample comprising genomic DNA of a subject and amplify a reference sequence in the sample; a reagent reservoir containing at least a first primer configured to specifically hybridize to a first end of the at least one reference sequence, wherein the reference sequence has at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114
  • FIG. 1A shows the decimal point calculated copy number of IRS2 as determined by qPCR with an RNaseP reference assay.
  • FIG. 1B shows the rounded copy number of IRS2 as determined by qPCR with an RNaseP reference assay.
  • FIG. 2A shows the decimal point calculated copy number of IRS2 as determined by qPCR with a reference assay based on SEQ ID NO:1-8.
  • FIG. 2B shows the rounded copy number of IRS2 as determined by qPCR with a reference assay based on SEQ ID NO:1-8.
  • FIG. 3A shows the decimal point calculated copy number of IRS2 as determined by qPCR with a reference assay based on SEQ ID NO:9-13.
  • FIG. 3B shows the rounded copy number of IRS2 as determined by qPCR with a reference assay based on SEQ ID NO:9-13.
  • Various embodiments of the present disclosure provide reference sequences that are relatively resistant to cancer-induced genomic abnormalities and/or FFPE-induced nucleic acid modifications. More specifically, the disclosure provides target sequences in the genome that are repeated multiple times, across many chromosomes, and demonstrate substantially normal copy number and resistance to severe modifications and fragmentation, even in cancer cells subjected to FFPE.
  • the present disclosure relates to a method, comprising amplifying a nucleic acid sequence of interest in a sample comprising genomic DNA of a subject; amplifying a reference nucleic acid sequence in the sample, wherein at least one copy of the reference nucleic acid sequence is present on each of at least ten chromosomes of the genomic DNA of the subject; quantifying the amplified sequence of interest relative to the amplified reference sequence; and determining a copy number of the sequence of interest from the relative quantified amplified sequence of interest.
  • Amplifying may be performed by any technique known to the person of ordinary skill in the art. Desirably, amplifying may be performed by a technique which permits quantification of the sequence of interest relative to the reference sequence. Exemplary techniques include, but are not limited to, polymerase chain reaction (PCR) (Saiki et al. (1985) Science 230: 1350), quantitative real-time PCR (qPCR), digital PCR, ligase chain reaction (LCR) (Landegren et al. (1988) Science 241:1077-1080), helicase-dependent amplification (HDA) (Vincent et al. (2004) EMBO rep 5(8):795-800), thermostable HDA (tHDA) (An et al.
  • PCR polymerase chain reaction
  • qPCR quantitative real-time PCR
  • digital PCR digital PCR
  • LCR ligase chain reaction
  • HDA helicase-dependent amplification
  • tHDA thermostable HDA
  • TMA transcription mediated amplification
  • NEAR nicking enzyme amplification reaction
  • EXPAR exponential amplification reaction
  • LAMP loop mediated isothermal amplification
  • RPA recombinase polymerase amplification
  • amplification is performed by TaqMan quantitative polymerase chain reaction (qPCR).
  • qPCR platform assays use two genome targets together to determine the copy number of a gene or region of the genome in a test sample.
  • One of the genome targets is a qPCR assay for the target of interest (TOI), and the second is a qPCR reference assay for what is assumed to be a normal, unmodified region of the genome.
  • TOI target of interest
  • the two assays are run simultaneously and in parallel on the same test sample.
  • the Cq values of each assay (indicative of the relative amount of TOI or reference amplicon) may be determined by techniques known to the person of ordinary skill in the art and/or described in more detail below, and a delta Cq between them is calculated.
  • This calculated delta Cq may then be compared to a delta Cq that is representative of a known copy number for the TOI.
  • the representative delta Cq may be a delta Cq determined from a sample known to be normal (i.e., having a copy number of 2, one copy from each of a pair of chromosomes).
  • This final calculated delta delta Cq between test sample and known sample/value may then be transformed into a decimal number or an integer number representing the copy number of the gene or region of genome in the test sample.
  • the challenge in cancer FFPE samples is in the ability to find a reference genome target (qPCR reference assay target) that is both normal and relatively unmodified by fixation and embedding. Additionally or alternatively, for some samples the ability to find a reference genome target may be complicated by a particular disease state, which includes but is not limited to cancer, where a potential reference genomic target may be altered by the disease state and is itself multiplied relative to its typical population.
  • nucleic acid sequence from the genomic DNA of a subject and of interest to the user of the method may be amplified and quantified according to the method.
  • the sequence of interest may be at least a portion of a gene which has an association with a disease.
  • the sample may be any tissue likely or possibly containing the nucleic acid sequence of interest in genomic DNA.
  • the method may be used to amplify and quantify a sequence of interest from tissue suspected of being cancer tissue, including tissue which has been subjected to formalin fixing and paraffin embedding (FFPE) prior to the amplifying the sequence of interest and amplifying the reference sequence.
  • the sequence of interest may be at least a portion of a gene for which there exists a correlation between the gene's copy number and the presence and/or stage of a cancer.
  • any reference nucleic acid sequence known or expected to be present in the genomic DNA of the sample may be amplified.
  • any particular locus of a copy of a reference nucleic acid sequence may have undergone a recombination event, an aneuploidy event, or the like.
  • the number of copies of the reference sequence in the sample may differ from that expected by simple counting of the number of loci of the reference sequence in a non-diseased sample from the subject or a member of the subject's species.
  • the sample comprises at least one copy of the reference nucleic acid sequence on each of at least ten chromosomes of the genomic DNA of the subject.
  • the presence of multiple, physically dispersed copies of the reference sequence may smooth or average out the effects of individual disruptions or duplications of various loci.
  • the reference sequence has at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, chr5-180756063-180768074, chr6-17092
  • the first minimum number may be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 copies.
  • the second minimum number may be 5, 6, 7, 8, 9, 10, or 11 chromosomes.
  • the first and second minimum numbers may be enumerated, estimated, or predicted based on any available human reference genome.
  • the reference sequence has at least 80% sequence identity to at least one of
  • the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:1-8.
  • the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:9-13.
  • a first set of sequences correspond to sequences found in the human genome at chr1:121836-121905, chr1:243203810-243203879, chr1:341419+341488, chr1:648175-648244, chr2:243071825+243071894, chr3:197962362+197962431, chr4:119569113+119569182, chr5:180768034+180768103, chr6:132997-133066, chr6:170922434+170922503, chr10:38753924+38753993, chr11:114056-114125, chr16:90251439+90251508, chr19:183990-184059, chr20:62933558+62933627, chrUn_g1000227:58864-58933, chrY:26436540+26436609,
  • a second set of sequences, SEQ ID NO:9-13, correspond to sequences found in the human genome at chr1:224126101-224126167, chr1:228152189+228152255, chr1:243203891-243203957, chr1:341341+341407, chr1:648256-648322, chr2:243071747+243071813, chr3:197962284+197962350, chr4:119569035+119569101, chr5:180767956+180768022, chr6:133078-133144, chr6:170922356+170922422, chr8:143260-143326, chr10:38753846+38753912, chr11:114137-114203, chr16:90251361+90251427, chr19:184071-184137, chr20:62933480+
  • each of the first set and the second set of sequences are both highly repeated ( ⁇ 20 copies in the human genome), physically dispersed throughout the human genome, and relatively more resistant to disruption and/or duplication by FFPE than typical genomic DNA sequences.
  • a sequence having at least 80% identity to one or more of SEQ ID NO:1-13 may be particularly suitable as a reference sequence, especially in samples suspected of being cancer tissue, particular FFPE-processed tissue.
  • the amplifying steps yield an amplified sequence of interest and an amplified reference sequence.
  • the amplifying steps yield an amplified sequence of interest and an amplified reference sequence.
  • the relative amounts of the amplified sequence of interest and the amplified reference sequence will be proportional to their copy number in the genomic DNA of the sample.
  • the method may comprise quantifying the amplified sequence of interest relative to the amplified reference sequence.
  • the quantifying may be performed by any technique known to the person of ordinary skill in the art. For example, by the use of two probes, each comprising a fluorescent moiety at a first end and a quencher for that fluorescent moiety at a second end, with one probe specifically hybridizing to the sequence of interest and the other specifically hybridizing to the reference sequence, in TaqMan qPCR, cleavage of the quencher by the action of Taq polymerase will generate a fluorescence signal proportional to the amount of probe hybridized to the sequence of interest or the reference sequence.
  • the relative quantity of the amplified sequence of interest would be 0.2. (As will be apparent to the person of ordinary skill in the art, alternative mathematically equivalent expressions may be used to arrive at a relative quantity).
  • amplification of the TOI and the reference sequence may be omitted.
  • Techniques for quantifying non-amplified nucleic acid sequences are known to the person of ordinary skill in the art.
  • fold change refers to the amount of amplified product (which relates to the copy number) in the sequence of interest relative to that of the reference genome target.
  • Fold change can be quantified using any of several available methods, including but not limited to those described by Livak, et al. (Methods, 25:402-408 (2001)), commercially available products such as CopyCallerTM (Applied Biosystems), or any other suitable algorithm for comparing amounts of fluorescence signals.
  • fold change is determined by comparing the C T of the sequence of interest to the C T of the reference genome target.
  • Some suitable algorithms include but are not limited to, the methods described in U.S. application Ser. No. 13/107,786, “Karyotyping Assay” filed on May 13, 2011, the disclosure of which is hereby incorporated by reference in its entirety.
  • the quantifying step yields a relative quantified amplified sequence of interest.
  • the method may then comprise determining a copy number of the sequence of interest from the relative quantified amplified sequence of interest. Determining requires an indication of the copy number of the reference sequence. Such an indication may be provided by analysis of the genome of a non-diseased sample from the subject or one or more members of the subject's species. This technique may be especially suitable, regarding samples suspected of being cancer tissue, for a reference sequence that is one or more of highly repeated, physically dispersed, and relatively resistant to disruption and/or duplication by FFPE.
  • the copy number of a reference sequence having at least 80% identity to one or more of SEQ ID NO:1-13 in a non-diseased sample may be expected to be substantially equal to the copy number of the reference sequence in a sample suspected of being cancer tissue.
  • the copy number of the reference sequence is 20
  • the determined copy number of the sequence of interest may be used for any purpose which would commend itself to the person of ordinary skill in the art.
  • the method may further comprise diagnosing the subject as having a cancer-related biomarker, based on the sequence of interest being associated with the cancer and the copy number being indicative of the cancer.
  • the present disclosure relates to a kit comprising a first probe which specifically hybridizes to at least a portion of at least one reference sequence having at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165
  • the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:1-31.
  • the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:1-13.
  • a “probe,” as used herein, refers to a compound comprising a nucleic acid sequence and a detectable moiety. As such, and for the avoidance of doubt, any “probe” referred to herein is non-naturally occurring.
  • the first probe comprises a nucleic acid sequence configured to specifically hybridize to at least the portion of the at least one reference sequence, a fluorescent reporter at a first end of the nucleic acid sequence, and a fluorescent quencher at a second end of the nucleic acid sequence.
  • the nucleic acid sequence is configured to specifically hybridize to the entirety of at least one reference sequence.
  • the reference sequence has at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% sequence identity to at least one of SEQ ID NO:1-13.
  • the first probe may allow the detection of at least the portion of the at least one reference sequence.
  • the kit may comprise other components.
  • the kit may further comprise a first primer configured to specifically hybridize to a first end of the at least one reference sequence, and a second primer configured to specifically hybridize to a sequence complementary to a second end of the at least one reference sequence.
  • primers nucleic acid molecules which, in the presence of the at least one reference sequence and other reagent(s), may allow amplification of the at least one reference sequence.
  • the kit may further comprise a second probe which specifically hybridizes to at least a portion of at least one nucleic acid sequence of interest.
  • the second probe may have the same characteristics as the first probe described above.
  • nucleic acid sequence of interest may be the hybridization target of the second probe.
  • sequence of interest is a portion or the entirety of a gene associated with a cancer.
  • the kit may further comprise a third primer configured to specifically hybridize to a first end of the at least one nucleic acid sequence of interest, and a fourth primer configured to specifically hybridize to a sequence complementary to a second end of the at least one nucleic acid sequence of interest.
  • the present disclosure relates to a composition, comprising a first probe which specifically hybridizes to at least a portion of at least one reference sequence having at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-
  • the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:1-31.
  • the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:1-13.
  • the first probe may be substantially the same as the first probe of the kit, described above.
  • the composition may further comprise one or more of (i) a first primer configured to specifically hybridize to a first end of at least one reference sequence, and a second primer configured to specifically hybridize to a sequence complementary to a second end of at least one reference sequence; (ii) a second probe which specifically hybridizes to at least a portion of at least one nucleic acid sequence of interest; or (iii) a third primer configured to specifically hybridize to a first end of at least one nucleic acid sequence of interest, and a fourth primer configured to specifically hybridize to a sequence complementary to a second end of at least one nucleic acid sequence of interest, substantially the same as the corresponding further component(s) of the kit, described above.
  • the present disclosure relates to a system, comprising:
  • a nucleic acid amplifier configured to amplify a nucleic acid sequence of interest in a sample comprising genomic DNA of a subject and amplify a reference sequence in the sample;
  • a reagent reservoir containing at least a first primer configured to specifically hybridize to a first end of at least one reference sequence, wherein the reference sequence has at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-
  • a detector configured to provide a first indication relating to an amount of the amplified sequence of interest and a second indication relating to an amount of the amplified reference sequence
  • a controller configured to quantify the amplified sequence of interest relative to the amplified reference sequence, based at least in part on the first indication and the second indication; and determine a copy number of the sequence of interest from the relative quantified amplified sequence of interest.
  • nucleic acid amplifiers are known to the person of ordinary skill in the art. Generally, nucleic acid amplifiers use one or more primers and one or more chemical or enzymatic agents to copy a template nucleic acid sequence, such as a sequence of interest or a reference sequence. Such copying can be cycled multiple times to yield relatively large amounts of the sequence of interest and the reference sequence. Desirably, the nucleic acid amplifier is configured to amplify the sequence of interest and the reference sequence simultaneously and in parallel, e.g., by adding different sets of primers, one specific to the sequence of interest and the other specific to the reference sequence, to otherwise identical reaction solutions, such as in different wells of a multi-well plate.
  • the reagent reservoir containing at least a first primer configured to specifically hybridize to a first end of the at least one reference sequence, wherein the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:1-31, such as SEQ ID NO:1-13, and a second primer configured to specifically hybridize to a sequence complementary to a second end of the at least one reference sequence.
  • the system also comprises a detector.
  • the detector may be configured to detect a probe for the sequence of interest, the reference sequence, or both. Upon detection, the detector may perform various signal processing and/or analysis operations to provide a first indication relating to an amount of the amplified sequence of interest and a second indication relating to an amount of the amplified reference sequence.
  • the system also comprises a controller.
  • the controller may be configured to quantify the amplified sequence of interest relative to the amplified reference sequence, based at least in part on the first indication and the second indication; and determine a copy number of the sequence of interest from the relative quantified amplified sequence of interest. It may store the determined copy number in a memory, display it to a user, write it to a computer-readable file, or the like.
  • the controller may be configured to diagnose the subject as having a cancer-related biomarker, based on the sequence of interest being associated with the cancer and the copy number being indicative of the cancer.
  • nucleic acid amplifier the reagent reservoir, the detector, and the controller have been described separately above, any two or more thereof may be components of a single apparatus.
  • the disclosure provides:
  • a method comprising:amplifying a nucleic acid sequence of interest in a sample comprising genomic DNA of a subject;amplifying a reference sequence in the sample, wherein the reference sequence has at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144
  • the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NOs: 1-31.
  • the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NO:1-13.
  • the sample can include tissue suspected of being cancer tissue.
  • the sample has been subjected to formalin fixing and paraffin embedding (FFPE) prior to amplifying the sequence of interest and amplifying the reference sequence.
  • FFPE formalin fixing and paraffin embedding
  • the method can also include: diagnosing the subject as having a cancer-related biomarker, based on the sequence of interest being associated with the cancer and the copy number being indicative of the cancer.
  • amplifying the sequence of interest and amplifying the reference sequence can be performed by TaqMan quantitative polymerase chain reaction (qPCR).
  • a kit comprising:a first probe which specifically hybridizes to at least a portion of at least one reference sequence having at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, ch
  • the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NO:1-31.
  • the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NO:1-13.
  • the first probe can include a nucleic acid sequence configured to specifically hybridize to at least the portion of the at least one reference sequence, a fluorescent reporter at a first end of the nucleic acid sequence, and a fluorescent quencher at a second end of the nucleic acid sequence.
  • the kit can further include: a first primer configured to specifically hybridize to a first end of the at least one reference sequence, and a second primer configured to specifically hybridize to a sequence complementary to a second end of the at least one reference sequence.
  • the kit can further include: a second probe which specifically hybridizes to at least a portion of at least one nucleic acid sequence of interest.
  • the kit can further include: a third primer configured to specifically hybridize to a first end of the at least one nucleic acid sequence of interest, and a fourth primer configured to specifically hybridize to a sequence complementary to a second end of the at least one nucleic acid sequence of interest.
  • a composition that includes: a first probe which specifically hybridizes to at least a portion of at least one reference sequence having at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, ch
  • the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NO:1-31.
  • the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NO:1-13.
  • the first probe can include a nucleic acid sequence configured to specifically hybridize to at least the portion of the at least one reference sequence, a fluorescent reporter at a first end of the nucleic acid sequence, and a fluorescent quencher at a second end of the nucleic acid sequence.
  • the composition can further include: a first primer configured to specifically hybridize to a first end of the at least one reference sequence, and a second primer configured to specifically hybridize to a sequence complementary to a second end of the at least one reference sequence.
  • composition can further include: a second probe which specifically hybridizes to at least a portion of at least one nucleic acid sequence of interest.
  • the composition can further include: a third primer configured to specifically hybridize to a first end of the at least one nucleic acid sequence of interest, and a fourth primer configured to specifically hybridize to a sequence complementary to a second end of the at least one nucleic acid sequence of interest.
  • a system that includes: a nucleic acid amplifier configured to amplify a nucleic acid sequence of interest in a sample comprising genomic DNA of a subject and amplify a reference sequence in the sample, a reagent reservoir containing at least a first primer configured to specifically hybridize to a first end of the at least one reference sequence, wherein the reference sequence has at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chrl-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480
  • the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NO:1-31.
  • the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NO:1-13.
  • the sample can include tissue suspected of being cancer tissue.
  • the controller is further configured to indicate the subject as having a cancer-related biomarker, based on the sequence of interest being associated with the cancer and the copy number being indicative of the cancer.
  • the nucleic acid amplifier is configured to amplify the sequence of interest and amplify the reference sequence by TaqMan quantitative polymerase chain reaction (qPCR).
  • qPCR TaqMan quantitative polymerase chain reaction
  • the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NO:1-38.
  • the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NO:1-13.
  • the sample includes tissue suspected of being cancer tissue.
  • the sample has been subjected to formalin fixing and paraffin embedding (FFPE) prior to amplifying the sequence of interest and amplifying the reference sequence.
  • FFPE formalin fixing and paraffin embedding
  • the method can further include: diagnosing the subject as having a cancer-related biomarker, based on the sequence of interest being associated with the cancer and the copy number being indicative of the cancer.
  • SEQ ID NO:1-13 were identified by a two-stage process.
  • a bioinformatics algorithm was used to identify candidate targets in the genome that met certain criteria associated with substantially normal copy number, even in cancer cells subjected to FFPE.
  • sequences suspected of being relatively resistant to copy number abnormalities in cancer cells and/or cells subjected to FFPE were used to query publicly-available human genomic databases, and only those sequences returning multiple hits were considered as candidate targets for further testing.
  • SEQ ID NO:1 The first stage identified SEQ ID NO:1-31.
  • SEQ ID NO:2-8 and 10-13 are located in the genome at the loci given supra.
  • SEQ ID NO:14-31 are located in the genome at least at the following loci:
  • the final round of testing evaluated the performance of these two de novo qPCR multicopy reference assays, a conventional qPCR single copy reference assay (RNaseP) and five qPCR TOI assays for the IRS2 gene.
  • the qPCR assays all used as template genomic DNA extracted from 35 colorectal normal tissue samples subjected to FFPE. All assays were performed in duplicate, with the reference assay and target of interest assay run in separate wells to generate accurate Cq values.
  • the first multicopy reference assay corresponding to SEQ ID NO:1-8, used a first set comprising forward primer, reverse primer, and probe sequence.
  • the second multicopy reference assay corresponding to SEQ ID NO:9-13, used a second set comprising forward primer, reverse primer, and probe sequence.
  • FIGS. 1A-3B A snapshot summary of the results is provided in FIGS. 1A-3B for each of the three reference assays: RNaseP ( FIGS. 1A-1B ), SEQ ID NO:1-8 ( FIGS. 2A-2B ), and SEQ ID NO:9-13 ( FIGS. 3A-3B ).
  • the copy number is plotted on the y-axis and the 35 samples in duplicate times the five different IRS2 TOI assays are plotted on the x-axis.
  • Each figure contains 350 data points.
  • compositions, methods, and/or systems disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this disclosure have been described in terms of particular embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions, methods, and/or systems and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the disclosure. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the disclosure as defined by the appended claims.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Cell Biology (AREA)

Abstract

A method, comprising amplifying a nucleic acid sequence of interest in a sample comprising genomic DNA of a subject; amplifying a reference nucleic acid sequence in the sample; quantifying the amplified sequence of interest relative to the amplified reference sequence; and determining a copy number of the sequence of interest from the relative quantified amplified sequence of interest. The reference sequence may have at least 80% sequence identity to at least one of SEQ ID NO:1-38, such as SEQ ID NO:1-13. Also disclosed are kits and compositions, each comprising a first probe which specifically hybridizes to at least a portion of at least one reference sequence. Also disclosed is a system configured to perform the above method.

Description

    BACKGROUND
  • Information relating to the copy number of a target of interest in the genome of a biological sample may be desirable for a number of purposes, including basic research and clinical diagnosis of various diseases. One class of diseases where the copy number of a target of interest may be particularly desirable to know is cancer. Numerous cancers present with abnormal copy numbers of one or more genes. In many cases, there exists a positive correlation between copy number and the existence and/or progression of cancer. Therefore, determining the copy number of a target of interest in a sample from a patient of tissue suspected of being cancer tissue may be useful, for example, in diagnosing, treating, and/or monitoring the course of the patient's cancer.
  • To date, quantitative polymerase chain reaction (qPCR) has been under consideration as a molecular technique for determining copy number of a target of interest. To determine copy number of a target of interest, qPCR may require the simultaneous amplification of both the target of interest and a reference sequence in the genome of the sample. From the relative quantities of the target of interest amplicon and the reference sequence amplicon, the relative copy numbers of the target of interest and the reference sequence can be determined, and assuming the absolute copy number of the reference sequence is known, the copy number of the target of interest may be determined.
  • However, when attempting to apply qPCR to determine the copy number of a target of interest in a cancer cell, the technique may be rendered difficult as a result of one or both of the random, evolving genomic abnormalities (e.g., aneuploidy) found in cancer cells and the modifications to nucleic acids that may occur when tissue samples are archived by formalin fixing and paraffin embedding (FFPE).
  • Genomic abnormalities of various types are known to occur in cancer cells, and increase in their quantity, distribution, and complexity as the cancer cells are replicated over time. These genomic abnormalities include gene deletions and multiplications, some of which may be related to a specific function in humans and common to certain cancer types, while others may have no overt effect or association with disease. As a result, a reference sequence of interest may undergo deletion and/or multiplication in the genome of a cancer cell, thereby making it very difficult to determine the absolute copy number of the reference sequence.
  • Modifications to the nucleic acids (DNA and RNA), such as cross linking of nucleotides to themselves or proteins, depurination of nucleotides, and fragmentation of the nucleic acids are known to occur as part of the archiving of cancer samples by the FFPE method. However, the locations and extent of these modifications are random and vary greatly across FFPE samples, due in large part to one or more factors, such as variability in the sample tissue itself, reagents used in fixation and embedding, and user preferred variations in the FFPE method at different labs. These effects also make it difficult or impossible to determine the absolute copy number of the reference sequence.
  • Both of these observations provide significant challenges to current molecular genetic assays and tests for DNA level copy number variation, such as qPCR.
  • Therefore, there exists a need for the selection of reference sequences that are relatively resistant to cancer-induced genomic abnormalities and/or FFPE-induced nucleic acid modifications.
    • SUMMARY OF THE DISCLOSURE
  • In one embodiment, the present disclosure relates to a method, comprising quantifying a nucleic acid sequence of interest relative to a reference nucleic acid sequence, wherein at least a first minimum number of copies of the reference nucleic acid sequence is present on each of at least a second minimum number of chromosomes of the genomic DNA of the subject; and determining a copy number of the sequence of interest from the relative quantified amplified sequence of interest.
  • In some embodiments, the method may further comprise amplifying the nucleic acid sequence of interest in a sample comprising genomic DNA of a subject; and amplifying the reference nucleic acid sequence in the sample; prior to quantifying.
  • In one embodiment, the reference sequence may have at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, chr5-180756063-180768074, chr6-170921836-170922549, chr7-39837560-63231088, chr7-128296352-128298474, chr8-143133-150475, chr9-49679-49771, chrY-26424506-27537936, or chr6-132951-145064; the at least one portion is present in at least a first minimum number of copies in the genome; and at least one copy of the at least one portion is present on each of at least a second minimum number of chromosomes.
  • In a particular embodiment, the reference nucleic acid sequence may have at least 80% sequence identity to at least one of
  • (SEQ ID NO: 1)
    GGCTGYTTGCRGTAGTWRTSTRKSWRSMRSMMRMWSRMYGSMSRCARRSRA
    RRMARWYWSTWDVWAKKMN,
    (SEQ ID NO: 2)
    GGCTGCTTGCAGTAGTTGTGTAGCAGCAGCACAATGGCCGCAGACAAGGAA
    AACAGTTTCTAGGAATTCC,
    (SEQ ID NO: 3)
    GGCTGCTTGCGGTAGTTATGTAGCAGCAGCACAATGGCCGCAGACAAGGAA
    AACAGTTTCTAGGAATTCC,
    (SEQ ID NO: 4)
    GGCTGCTTGCGGTAGTTGTCTAGCAGCAGCACAATGGCCGCAGACAAGGAA
    AACAGTTTCTAGGAATTCC,
    (SEQ ID NO: 5)
    GGCTGCTTGCGGTAGTTGTGTAGCAGCAGCACAATGGCCGCAGACAAGGAA
    AACAGTTTCTAAAAATTCC,
    (SEQ ID NO: 6)
    GGCTGCTTGCGGTAGTTGTGTAGCAGCAGCACAATGGCCGCAGACAAGGAA
    AACAGTTTCTAGGAATTCC,
    (SEQ ID NO: 7)
    GGCTGCTTGCGGTAGTTGTGTAGCAGCAGCACAATGGCCGCAGACAAGGAA
    AACAGTTTCTAGGAATTCN,
    (SEQ ID NO: 8)
    GGCTGTTTGCGGTAGTAGTCTGTGTAGCAGCAGCACAATGGCCGCAGACGA
    GGAAAACAGTTTCTAGGAA,
    (SEQ ID NO: 9)
    AGTGCAGYRWTGYTGACTCTTCCAAGCTTAACATTTCTCASAARTCAATTA
    GCTTTGTACTGGGAGG,
    (SEQ ID NO: 10)
    AGTGCAGCAATGTTGACTCTTCCAAGCTTAACATTTCTCAGAAGTCAATTA
    GCTTTGTACTGGGAGG,
    (SEQ ID NO: 11)
    AGTGCAGCGATGCTGACTCTTCCAAGCTTAACATTTCTCACAAGTCAATTA
    GCTTTGTACTGGGAGG,
    (SEQ ID NO: 12)
    AGTGCAGCGTTGCTGACTCTTCCAAGCTTAACATTTCTCACAAATCAATTA
    GCTTTGTACTGGGAGG,
    (SEQ ID NO: 13)
    AGTGCAGTGATGCTGACTCTTCCAAGCTTAACATTTCTCACAAGTCAATTA
    GCTTTGTACTGGGAGG,
    (SEQ ID NO: 14)
    GTGTAGCAGCAGCACAATGGCCGCAGACAAGGAAAACAGTTTCTAGGAATT
    CCTCGTATATAATTTTATATTTTTGACAAGATTAATGACCCATGCTCC,
    (SEQ ID NO: 15)
    TGCARMGATGCTGACTCTTCCAAGCTTAACATTTCTCACAAGTCAATTAGC
    TTTGTACTGGGAGG,
    (SEQ ID NO: 16)
    TGCTGACTCTTCCAAGCTTAACATTTCTCACAAGTCAATTAGCTTTGTACT
    GGGAGGAGGGCGTGAAGGGCTGCTTGCG,
    (SEQ ID NO: 17)
    CAAGGGACAAGGAAAAATTATCCAAACATTGTTTAAAACAATCATCATTAA
    TTAGTAACACTTATCCAGGGGGGTTTTTAACCTTTCCCCCACTCAASGATT
    ATTCTAATGTCAGAGTAGAATAAAAAATAAGTGCARMGATGCTGAC,
    (SEQ ID NO: 18)
    GGAGGAGGAAAATAGGTAGTTTTTCAAAAGTTTTCAAAAATATGAAAAGAA
    GAAATGAAATGGTACTTGGAAGAGATTGTTGAAATGGGAGAGACTATGGTG
    GC,
    (SEQ ID NO: 19)
    CAACTAAAAGGCAATGTCACTCCAATAATCACCAGAGTAATCAATTTGCTT
    ATTGCTGTCCCTTTAAATATAGTTCTCTGG,
    (SEQ ID NO: 20)
    GGAGAGACTATGGTGGCTTGTTTAGAAGCAGTTGAGATAGATCCAATTGAG
    ATAGAGATATTGAGTATATAAACAAAAGAATGACAAATTAATAGTGTAATG
    GATAACTTGACTTTGGCA,
    (SEQ ID NO: 21)
    GTGTAATGGATAACTTGACTTTGGCAAATATTGTGAATTTTTGTGAAAGTA
    CAACTAAAAGGCAATGTCACTCCAATAATCACCAG,
    (SEQ ID NO: 22)
    GTAATCAATTTGCTTATTGCTGTCCCTTTAAATATAGTTCTCTGGTATCAA
    CTAACATGTTTTTAACTAATGATGCTTCTTAAAGAAAAGGGAAAAGACCT,
    (SEQ ID NO: 23)
    CCCTGGGCCCCTCAGGGGAGTCCCTGCTGGACAGTGAGACAGAGAATGACC
    ATGATGATGCTTTCCT,
    (SEQ ID NO: 24)
    GGGTTTATGTTTGATATRTAATGTAATTTTCTAATGCTAAATCAAGTGGTA
    ATTTTGTTAGTCAAGTTGATTTAGTGGCTTGGGAAGAAAGCT,
    (SEQ ID NO: 25)
    GAGACCCCCAGGTGTTGAGGCAGGGCTGGGGTGTCCCCTTCCAACCAGGCT
    GTCAAGGCCCCAACTCTGGGGCAGAGGCAGTGGCAGGG,
    (SEQ ID NO: 26)
    CATCCGTTTCACCTGCAGTTGAAGATCCGTGAGGTGCCCAGAAGATCATGC
    AGTCAWCAGTCCCACG,
    (SEQ ID NO: 27)
    GAKATAAGGAAGCTCGAGGAAGAGAAAAAACAACTGGAAGGAGAAATCATA
    GATTTTTATAAAATGAMAGCTGCCTCTGAAGC,
    (SEQ ID NO: 28)
    CCGTTTTGGAGGAGGAACAGATTCCATGTCCACTAGAATGGAATGAACAAG
    AAATGGAGGAGGAAAATAGGTAGTTTTTCAAAAGTTTTCAAAAATATGAAA
    AGAAGAAATGAAATGGTACTTGGAAGAGATTGTTGAAATGGGA,
    (SEQ ID NO: 29)
    TGCTTCTTAAAGAAAAGGGAAAAGACCTTTTTCTTTCTTTCAGTCTTCAAT
    GATTCACTGCTTCATCTCGCTCCACCAAAGATAAATGAAATCTACATCTC
    T,
    (SEQ ID NO: 30)
    CTTTCCCCCACTCAASGATTATTCTAATGTCAGAGTAGAATAAAAAATAAG
    TGCARMGATGCTGACTCTTCCAAGCTTAACATTTCTCA,
    or
    (SEQ ID NO: 31)
    GGGAGGAGGGCGTGAAGGGCTGCTTGCGGTAGTTGTGTAGCAGCAGCACAA
    TGGCCGCAGACAAG.
  • In another embodiment, the present disclosure relates to a kit, comprising a first probe which specifically hybridizes to at least a portion of at least one reference sequence that has at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, chr5-180756063-180768074, chr6-170921836-170922549, chr7-39837560-63231088, chr7-128296352-128298474, chr8-143133-150475, chr9-49679-49771, chrY-26424506-27537936, or chr6-132951-145064; the at least one portion is present in at least a first minimum number of copies in the genome; and at least one copy of the at least one portion is present on each of at least a second minimum number of chromosomes.
  • In still another embodiment, the present disclosure relates to a composition, comprising a first probe which specifically hybridizes to at least a portion of at least one reference sequence that has at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chrl-222643865-228172047, chrl-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, chr5-180756063-180768074, chr6-170921836-170922549, chr7-39837560-63231088, chr7-128296352-128298474, chr8-143133-150475, chr9-49679-49771, chrY-26424506-27537936, or chr6-132951-145064; the at least one portion is present in at least a first minimum number of copies in the genome; and at least one copy of the at least one portion is present on each of at least a second minimum number of chromosomes.
  • In yet another embodiment, the present disclosure relates to a system, comprising a nucleic acid amplifier configured to amplify a nucleic acid sequence of interest in a sample comprising genomic DNA of a subject and amplify a reference sequence in the sample; a reagent reservoir containing at least a first primer configured to specifically hybridize to a first end of the at least one reference sequence, wherein the reference sequence has at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, chr5-180756063-180768074, chr6-170921836-170922549, chr7-39837560-63231088, chr7-128296352-128298474, chr8-143133-150475, chr9-49679-49771, chrY-26424506-27537936, or chr6-132951-145064; the at least one portion is present in at least a first minimum number of copies in the genome; and at least one copy of the at least one portion is present on each of at least a second minimum number of chromosomes, and a second primer configured to specifically hybridize to a sequence complementary to a second end of the at least one reference sequence,; a detector configured to provide a first indication relating to an amount of the amplified sequence of interest and a second indication relating to an amount of the amplified reference sequence; and a controller configured to quantify the amplified sequence of interest relative to the amplified reference sequence, based at least in part on the first indication and the second indication and determine a copy number of the sequence of interest from the relative quantified amplified sequence of interest.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure. The disclosure may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
  • FIG. 1A shows the decimal point calculated copy number of IRS2 as determined by qPCR with an RNaseP reference assay.
  • FIG. 1B shows the rounded copy number of IRS2 as determined by qPCR with an RNaseP reference assay.
  • FIG. 2A shows the decimal point calculated copy number of IRS2 as determined by qPCR with a reference assay based on SEQ ID NO:1-8.
  • FIG. 2B shows the rounded copy number of IRS2 as determined by qPCR with a reference assay based on SEQ ID NO:1-8.
  • FIG. 3A shows the decimal point calculated copy number of IRS2 as determined by qPCR with a reference assay based on SEQ ID NO:9-13.
  • FIG. 3B shows the rounded copy number of IRS2 as determined by qPCR with a reference assay based on SEQ ID NO:9-13.
    •  DESCRIPTION
  • Various embodiments of the present disclosure provide reference sequences that are relatively resistant to cancer-induced genomic abnormalities and/or FFPE-induced nucleic acid modifications. More specifically, the disclosure provides target sequences in the genome that are repeated multiple times, across many chromosomes, and demonstrate substantially normal copy number and resistance to severe modifications and fragmentation, even in cancer cells subjected to FFPE.
  • In one embodiment, the present disclosure relates to a method, comprising amplifying a nucleic acid sequence of interest in a sample comprising genomic DNA of a subject; amplifying a reference nucleic acid sequence in the sample, wherein at least one copy of the reference nucleic acid sequence is present on each of at least ten chromosomes of the genomic DNA of the subject; quantifying the amplified sequence of interest relative to the amplified reference sequence; and determining a copy number of the sequence of interest from the relative quantified amplified sequence of interest.
  • Amplifying may be performed by any technique known to the person of ordinary skill in the art. Desirably, amplifying may be performed by a technique which permits quantification of the sequence of interest relative to the reference sequence. Exemplary techniques include, but are not limited to, polymerase chain reaction (PCR) (Saiki et al. (1985) Science 230: 1350), quantitative real-time PCR (qPCR), digital PCR, ligase chain reaction (LCR) (Landegren et al. (1988) Science 241:1077-1080), helicase-dependent amplification (HDA) (Vincent et al. (2004) EMBO rep 5(8):795-800), thermostable HDA (tHDA) (An et al. (2005) J Biol Chem 280 (32):28952-28958), strand displacement amplification (SDA) (Walker et al. (1992) Nucleic Acids Res 20(7):16916), multiple displacement amplification (MDA) (Dean et al. (2002) Proc Natl Acad Sci USA 99(8): 5261-5266), rolling circle amplification (RCA) (Liu et al. (1996) J Am Chem Soc 118:1587-1594), restriction aided RCA (Wang et al. (2004) Genome Res 14:2357-2366), single primer isothermal amplification (SPIA) (Daffom et al. (2004) Biotechniques 37(5):854-7), transcription mediated amplification (TMA) (Vuorinen et al. (1995) J Clin Microbio133: 1856-1859), nicking enzyme amplification reaction (NEAR) (Maples et al. US2009017453), exponential amplification reaction (EXPAR) (Van Ness et al. (2003) Proc Natl Acad Sci USA 100 (8):4504-4509), loop mediated isothermal amplification (LAMP) (Notomi et al. (2000) Nucleic Acids Res 28(12):e63), recombinase polymerase amplification (RPA) (Piepenburg et al. (2006) PloS Biol 4(7): 1115-1120), nucleic acid sequence based amplification (NASBA) (Kievits et al. (1991) J Virol Methods 35:273-286), smart-amplification process (SMAP) (Mitani et al. (2007) Nat Methods 4(3):257-62), nanostring amplification (Geiss et al (2008) Nature Biotechnology 26:317-325; Schwanhausser et al (2011) Nature 473:337-342; commercially available as the nCounter® platform from NanoString Technologies, Seattle, WA), or next generation sequencing (NGS) (Rothberg et al (2011) Nature 475:348-352; Metzker M (2010) Nature Rev Genetics 11:31-46).
  • In a particular embodiment, amplification is performed by TaqMan quantitative polymerase chain reaction (qPCR).
  • Generally, qPCR platform assays use two genome targets together to determine the copy number of a gene or region of the genome in a test sample. One of the genome targets is a qPCR assay for the target of interest (TOI), and the second is a qPCR reference assay for what is assumed to be a normal, unmodified region of the genome. The two assays are run simultaneously and in parallel on the same test sample. After one or more cycles of the polymerase chain reaction, the Cq values of each assay (indicative of the relative amount of TOI or reference amplicon) may be determined by techniques known to the person of ordinary skill in the art and/or described in more detail below, and a delta Cq between them is calculated. This calculated delta Cq may then be compared to a delta Cq that is representative of a known copy number for the TOI. For example, the representative delta Cq may be a delta Cq determined from a sample known to be normal (i.e., having a copy number of 2, one copy from each of a pair of chromosomes). This final calculated delta delta Cq between test sample and known sample/value may then be transformed into a decimal number or an integer number representing the copy number of the gene or region of genome in the test sample.
  • For reasons described above, the challenge in cancer FFPE samples is in the ability to find a reference genome target (qPCR reference assay target) that is both normal and relatively unmodified by fixation and embedding. Additionally or alternatively, for some samples the ability to find a reference genome target may be complicated by a particular disease state, which includes but is not limited to cancer, where a potential reference genomic target may be altered by the disease state and is itself multiplied relative to its typical population.
  • Any nucleic acid sequence from the genomic DNA of a subject and of interest to the user of the method may be amplified and quantified according to the method. For example, the sequence of interest may be at least a portion of a gene which has an association with a disease. As will be apparent to the person of ordinary skill in the art, the sample may be any tissue likely or possibly containing the nucleic acid sequence of interest in genomic DNA.
  • The method may be used to amplify and quantify a sequence of interest from tissue suspected of being cancer tissue, including tissue which has been subjected to formalin fixing and paraffin embedding (FFPE) prior to the amplifying the sequence of interest and amplifying the reference sequence. In such a use, the sequence of interest may be at least a portion of a gene for which there exists a correlation between the gene's copy number and the presence and/or stage of a cancer.
  • Any reference nucleic acid sequence known or expected to be present in the genomic DNA of the sample may be amplified. However, a person of ordinary skill in the art will be aware that in many embodiments, such as those in which the sample is suspected of being cancer tissue, and especially a sample previously subject to FFPE, any particular locus of a copy of a reference nucleic acid sequence may have undergone a recombination event, an aneuploidy event, or the like. Thus, the number of copies of the reference sequence in the sample may differ from that expected by simple counting of the number of loci of the reference sequence in a non-diseased sample from the subject or a member of the subject's species.
  • Therefore, it is desirable that the sample comprises at least one copy of the reference nucleic acid sequence on each of at least ten chromosomes of the genomic DNA of the subject. The presence of multiple, physically dispersed copies of the reference sequence may smooth or average out the effects of individual disruptions or duplications of various loci.
  • In one embodiment, the reference sequence has at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, chr5-180756063-180768074, chr6-170921836-170922549, chr7-39837560-63231088, chr7-128296352-128298474, chr8-143133-150475, chr9-49679-49771, chrY-26424506-27537936, or chr6-132951-145064; the at least one portion is present in at least a first minimum number of copies in the genome; and at least one copy of the at least one portion is present on each of at least a second minimum number of chromosomes.
  • In one embodiment, the first minimum number may be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 copies. Independently, the second minimum number may be 5, 6, 7, 8, 9, 10, or 11 chromosomes. The first and second minimum numbers may be enumerated, estimated, or predicted based on any available human reference genome.
  • In a particular embodiment, the reference sequence has at least 80% sequence identity to at least one of
  • (SEQ ID NO: 1)
    GGCTGYTTGCRGTAGTWRTSTRKSWRSMRSMMRMWSRMYGSMSRCARRSRA
    RRMARWYWSTWDVWAKKMN,
    (SEQ ID NO: 2)
    GGCTGCTTGCAGTAGTTGTGTAGCAGCAGCACAATGGCCGCAGACAAGGAA
    AACAGTTTCTAGGAATTCC,
    (SEQ ID NO: 3)
    GGCTGCTTGCGGTAGTTATGTAGCAGCAGCACAATGGCCGCAGACAAGGAA
    AACAGTTTCTAGGAATTCC,
    (SEQ ID NO: 4)
    GGCTGCTTGCGGTAGTTGTCTAGCAGCAGCACAATGGCCGCAGACAAGGAA
    AACAGTTTCTAGGAATTCC,
    (SEQ ID NO: 5)
    GGCTGCTTGCGGTAGTTGTGTAGCAGCAGCACAATGGCCGCAGACAAGGAA
    AACAGTTTCTAAAAATTCC,
    (SEQ ID NO: 6)
    GGCTGCTTGCGGTAGTTGTGTAGCAGCAGCACAATGGCCGCAGACAAGGAA
    AACAGTTTCTAGGAATTCC,
    (SEQ ID NO: 7)
    GGCTGCTTGCGGTAGTTGTGTAGCAGCAGCACAATGGCCGCAGACAAGGAA
    AACAGTTTCTAGGAATTCN,
    (SEQ ID NO: 8)
    GGCTGTTTGCGGTAGTAGTCTGTGTAGCAGCAGCACAATGGCCGCAGACGA
    GGAAAACAGTTTCTAGGAA,
    (SEQ ID NO: 9)
    AGTGCAGYRWTGYTGACTCTTCCAAGCTTAACATTTCTCASAARTCAATTA
    GCTTTGTACTGGGAGG,
    (SEQ ID NO: 10)
    AGTGCAGCAATGTTGACTCTTCCAAGCTTAACATTTCTCAGAAGTCAATTA
    GCTTTGTACTGGGAGG,
    (SEQ ID NO: 11)
    AGTGCAGCGATGCTGACTCTTCCAAGCTTAACATTTCTCACAAGTCAATTA
    GCTTTGTACTGGGAGG,
    (SEQ ID NO: 12)
    AGTGCAGCGTTGCTGACTCTTCCAAGCTTAACATTTCTCACAAATCAATTA
    GCTTTGTACTGGGAGG,
    (SEQ ID NO: 13)
    AGTGCAGTGATGCTGACTCTTCCAAGCTTAACATTTCTCACAAGTCAATTA
    GCTTTGTACTGGGAGG,
    (SEQ ID NO: 14)
    GTGTAGCAGCAGCACAATGGCCGCAGACAAGGAAAACAGTTTCTAGGAATT
    CCTCGTATATAATTTTATATTTTTGACAAGATTAATGACCCATGCTCC,
    (SEQ ID NO: 15)
    TGCARMGATGCTGACTCTTCCAAGCTTAACATTTCTCACAAGTCAATTAGC
    TTTGTACTGGGAGG,
    (SEQ ID NO: 16)
    TGCTGACTCTTCCAAGCTTAACATTTCTCACAAGTCAATTAGCTTTGTACT
    GGGAGGAGGGCGTGAAGGGCTGCTTGCG,
    (SEQ ID NO: 17)
    CAAGGGACAAGGAAAAATTATCCAAACATTGTTTAAAACAATCATCATTAA
    TTAGTAACACTTATCCAGGGGGGTTTTTAACCTTTCCCCCACTCAASGATT
    ATTCTAATGTCAGAGTAGAATAAAAAATAAGTGCARMGATGCTGAC,
    (SEQ ID NO: 18)
    GGAGGAGGAAAATAGGTAGTTTTTCAAAAGTTTTCAAAAATATGAAAAGAA
    GAAATGAAATGGTACTTGGAAGAGATTGTTGAAATGGGAGAGACTATGGTG
    GC,
    (SEQ ID NO: 19)
    CAACTAAAAGGCAATGTCACTCCAATAATCACCAGAGTAATCAATTTGCTT
    ATTGCTGTCCCTTTAAATATAGTTCTCTGG,
    (SEQ ID NO: 20)
    GGAGAGACTATGGTGGCTTGTTTAGAAGCAGTTGAGATAGATCCAATTGAG
    ATAGAGATATTGAGTATATAAACAAAAGAATGACAAATTAATAGTGTAATG
    GATAACTTGACTTTGGCA,
    (SEQ ID NO: 21)
    GTGTAATGGATAACTTGACTTTGGCAAATATTGTGAATTTTTGTGAAAGTA
    CAACTAAAAGGCAATGTCACTCCAATAATCACCAG,
    (SEQ ID NO: 22)
    GTAATCAATTTGCTTATTGCTGTCCCTTTAAATATAGTTCTCTGGTATCAA
    CTAACATGTTTTTAACTAATGATGCTTCTTAAAGAAAAGGGAAAAGACCT,
    (SEQ ID NO: 23)
    CCCTGGGCCCCTCAGGGGAGTCCCTGCTGGACAGTGAGACAGAGAATGACC
    ATGATGATGCTTTCCT,
    (SEQ ID NO: 24)
    GGGTTTATGTTTGATATRTAATGTAATTTTCTAATGCTAAATCAAGTGGTA
    ATTTTGTTAGTCAAGTTGATTTAGTGGCTTGGGAAGAAAGCT,
    (SEQ ID NO: 25)
    GAGACCCCCAGGTGTTGAGGCAGGGCTGGGGTGTCCCCTTCCAACCAGGCT
    GTCAAGGCCCCAACTCTGGGGCAGAGGCAGTGGCAGGG,
    (SEQ ID NO: 26)
    CATCCGTTTCACCTGCAGTTGAAGATCCGTGAGGTGCCCAGAAGATCATGC
    AGTCAWCAGTCCCACG,
    (SEQ ID NO: 27)
    GAKATAAGGAAGCTCGAGGAAGAGAAAAAACAACTGGAAGGAGAAATCATA
    GATTTTTATAAAATGAMAGCTGCCTCTGAAGC,
    (SEQ ID NO: 28)
    CCGTTTTGGAGGAGGAACAGATTCCATGTCCACTAGAATGGAATGAACAAG
    AAATGGAGGAGGAAAATAGGTAGTTTTTCAAAAGTTTTCAAAAATATGAAA
    AGAAGAAATGAAATGGTACTTGGAAGAGATTGTTGAAATGGGA,
    (SEQ ID NO: 29)
    TGCTTCTTAAAGAAAAGGGAAAAGACCTTTTTCTTTCTTTCAGTCTTCAAT
    GATTCACTGCTTCATCTCGCTCCACCAAAGATAAATGAAATCTACATCTC
    T,
    (SEQ ID NO: 30)
    CTTTCCCCCACTCAASGATTATTCTAATGTCAGAGTAGAATAAAAAATAAG
    TGCARMGATGCTGACTCTTCCAAGCTTAACATTTCTCA,
    or
    (SEQ ID NO: 31)
    GGGAGGAGGGCGTGAAGGGCTGCTTGCGGTAGTTGTGTAGCAGCAGCACAA
    TGGCCGCAGACAAG.
  • In one embodiment, the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:1-8.
  • In one embodiment, the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:9-13.
  • A first set of sequences, SEQ ID NO:1-8, correspond to sequences found in the human genome at chr1:121836-121905, chr1:243203810-243203879, chr1:341419+341488, chr1:648175-648244, chr2:243071825+243071894, chr3:197962362+197962431, chr4:119569113+119569182, chr5:180768034+180768103, chr6:132997-133066, chr6:170922434+170922503, chr10:38753924+38753993, chr11:114056-114125, chr16:90251439+90251508, chr19:183990-184059, chr20:62933558+62933627, chrUn_g1000227:58864-58933, chrY:26436540+26436609, and chrY:27525831-27525900.
  • A second set of sequences, SEQ ID NO:9-13, correspond to sequences found in the human genome at chr1:224126101-224126167, chr1:228152189+228152255, chr1:243203891-243203957, chr1:341341+341407, chr1:648256-648322, chr2:243071747+243071813, chr3:197962284+197962350, chr4:119569035+119569101, chr5:180767956+180768022, chr6:133078-133144, chr6:170922356+170922422, chr8:143260-143326, chr10:38753846+38753912, chr11:114137-114203, chr16:90251361+90251427, chr19:184071-184137, chr20:62933480+62933546, and chrUn_gl000227:58945-59011.
  • In any nucleic acid sequence listing herein, the standard IUPAC table of naturally-occurring and degenerate nucleotides is used:
  • Symbol Description Bases represented
    A adenine A
    C cytosine C
    G guanine G
    T thymine T
    U uracil U
    W Weak A, T
    S Strong C, G
    M Amino A, C
    K Keto G, T
    R Purine A, G
    Y Pyrimidine C, T
    B Not adenine C, G, T
    D Not cytosine A, G, T
    H Not guanine A, C, T
    V Not thymine A, C, G
    N Any base (not a gap) A, C, G, T
  • Though not to be bound by theory, the present inventor has found that each of the first set and the second set of sequences are both highly repeated (˜20 copies in the human genome), physically dispersed throughout the human genome, and relatively more resistant to disruption and/or duplication by FFPE than typical genomic DNA sequences. As a result, a sequence having at least 80% identity to one or more of SEQ ID NO:1-13 may be particularly suitable as a reference sequence, especially in samples suspected of being cancer tissue, particular FFPE-processed tissue.
  • The amplifying steps yield an amplified sequence of interest and an amplified reference sequence. Generally, so long as performance of the amplifying steps is synchronized and amplification has not proceeded to an extent where the quantity of any reagent other than the amplified sequence of interest and the amplified reference sequence is rate-limiting, at any point, the relative amounts of the amplified sequence of interest and the amplified reference sequence will be proportional to their copy number in the genomic DNA of the sample.
  • Thus, the method may comprise quantifying the amplified sequence of interest relative to the amplified reference sequence. The quantifying may be performed by any technique known to the person of ordinary skill in the art. For example, by the use of two probes, each comprising a fluorescent moiety at a first end and a quencher for that fluorescent moiety at a second end, with one probe specifically hybridizing to the sequence of interest and the other specifically hybridizing to the reference sequence, in TaqMan qPCR, cleavage of the quencher by the action of Taq polymerase will generate a fluorescence signal proportional to the amount of probe hybridized to the sequence of interest or the reference sequence. Thus, in a simple hypothetical non-limiting example, if the fluorescence signal from the probe hybridizing to the reference sequence is five times more intense than the fluorescence signal from the probe hybridizing to the sequence of interest, the relative quantity of the amplified sequence of interest would be 0.2. (As will be apparent to the person of ordinary skill in the art, alternative mathematically equivalent expressions may be used to arrive at a relative quantity).
  • In some embodiments, amplification of the TOI and the reference sequence may be omitted. Techniques for quantifying non-amplified nucleic acid sequences are known to the person of ordinary skill in the art.
  • The measure of relative quantitation may be reported using the term “fold change”, which refers to the amount of amplified product (which relates to the copy number) in the sequence of interest relative to that of the reference genome target. Fold change can be quantified using any of several available methods, including but not limited to those described by Livak, et al. (Methods, 25:402-408 (2001)), commercially available products such as CopyCaller™ (Applied Biosystems), or any other suitable algorithm for comparing amounts of fluorescence signals. In many embodiments, fold change is determined by comparing the CT of the sequence of interest to the CT of the reference genome target. Some suitable algorithms include but are not limited to, the methods described in U.S. application Ser. No. 13/107,786, “Karyotyping Assay” filed on May 13, 2011, the disclosure of which is hereby incorporated by reference in its entirety.
  • The quantifying step yields a relative quantified amplified sequence of interest. The method may then comprise determining a copy number of the sequence of interest from the relative quantified amplified sequence of interest. Determining requires an indication of the copy number of the reference sequence. Such an indication may be provided by analysis of the genome of a non-diseased sample from the subject or one or more members of the subject's species. This technique may be especially suitable, regarding samples suspected of being cancer tissue, for a reference sequence that is one or more of highly repeated, physically dispersed, and relatively resistant to disruption and/or duplication by FFPE. For example, the copy number of a reference sequence having at least 80% identity to one or more of SEQ ID NO:1-13 in a non-diseased sample may be expected to be substantially equal to the copy number of the reference sequence in a sample suspected of being cancer tissue.
  • Continuing the simple hypothetical non-limiting example begun above, if the copy number of the reference sequence is 20, then the copy number of the amplified sequence of interest may be determined to be 20*0.2=4. (As should be apparent, this is a simple probe-based example of a copy number calculation. It is a routine matter for the person of ordinary skill in the art, having the benefit of the present disclosure, to perform copy number calculation for other assay techniques, such as qPCR.)
  • The determined copy number of the sequence of interest may be used for any purpose which would commend itself to the person of ordinary skill in the art. In a particular embodiment, the method may further comprise diagnosing the subject as having a cancer-related biomarker, based on the sequence of interest being associated with the cancer and the copy number being indicative of the cancer.
  • In one embodiment, the present disclosure relates to a kit comprising a first probe which specifically hybridizes to at least a portion of at least one reference sequence having at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, chr5-180756063-180768074, chr6-170921836-170922549, chr7-39837560-63231088, chr7-128296352-128298474, chr8-143133-150475, chr9-49679-49771, chrY-26424506-27537936, or chr6-132951-145064; the at least one portion is present in at least a first minimum number of copies in the genome; and at least one copy of the at least one portion is present on each of at least a second minimum number of chromosomes.
  • In a particular embodiment, the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:1-31.
  • In a more particular embodiment, the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:1-13.
  • A “probe,” as used herein, refers to a compound comprising a nucleic acid sequence and a detectable moiety. As such, and for the avoidance of doubt, any “probe” referred to herein is non-naturally occurring.
  • In one embodiment, the first probe comprises a nucleic acid sequence configured to specifically hybridize to at least the portion of the at least one reference sequence, a fluorescent reporter at a first end of the nucleic acid sequence, and a fluorescent quencher at a second end of the nucleic acid sequence.
  • In a further embodiment, the nucleic acid sequence is configured to specifically hybridize to the entirety of at least one reference sequence.
  • A percentage of sequence identity can be determined by any technique known to the person of ordinary skill in the art. In some embodiments, the reference sequence has at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% sequence identity to at least one of SEQ ID NO:1-13.
  • By use of techniques known to the person of ordinary skill in the art, the first probe may allow the detection of at least the portion of the at least one reference sequence.
  • In addition to the first probe, the kit may comprise other components. For example, the kit may further comprise a first primer configured to specifically hybridize to a first end of the at least one reference sequence, and a second primer configured to specifically hybridize to a sequence complementary to a second end of the at least one reference sequence.
  • By “primers” is meant nucleic acid molecules which, in the presence of the at least one reference sequence and other reagent(s), may allow amplification of the at least one reference sequence.
  • Alternatively or in addition, the kit may further comprise a second probe which specifically hybridizes to at least a portion of at least one nucleic acid sequence of interest. Other than the sequence to which it specifically hybridizes, the second probe may have the same characteristics as the first probe described above.
  • Any nucleic acid sequence of interest may be the hybridization target of the second probe. In one embodiment, the sequence of interest is a portion or the entirety of a gene associated with a cancer.
  • Alternatively or in addition, the kit may further comprise a third primer configured to specifically hybridize to a first end of the at least one nucleic acid sequence of interest, and a fourth primer configured to specifically hybridize to a sequence complementary to a second end of the at least one nucleic acid sequence of interest. In one embodiment, the present disclosure relates to a composition, comprising a first probe which specifically hybridizes to at least a portion of at least one reference sequence having at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, chr5-180756063-180768074, chr6-170921836-170922549, chr7-39837560-63231088, chr7-128296352-128298474, chr8-143133-150475, chr9-49679-49771, chrY-26424506-27537936, or chr6-132951-145064; the at least one portion is present in at least a first minimum number of copies in the genome; and at least one copy of the at least one portion is present on each of at least a second minimum number of chromosomes.
  • In a particular embodiment, the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:1-31.
  • In a more particular embodiment, the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:1-13.
  • The first probe may be substantially the same as the first probe of the kit, described above.
  • The composition may further comprise one or more of (i) a first primer configured to specifically hybridize to a first end of at least one reference sequence, and a second primer configured to specifically hybridize to a sequence complementary to a second end of at least one reference sequence; (ii) a second probe which specifically hybridizes to at least a portion of at least one nucleic acid sequence of interest; or (iii) a third primer configured to specifically hybridize to a first end of at least one nucleic acid sequence of interest, and a fourth primer configured to specifically hybridize to a sequence complementary to a second end of at least one nucleic acid sequence of interest, substantially the same as the corresponding further component(s) of the kit, described above.
  • In one embodiment, the present disclosure relates to a system, comprising:
  • a nucleic acid amplifier configured to amplify a nucleic acid sequence of interest in a sample comprising genomic DNA of a subject and amplify a reference sequence in the sample;
  • a reagent reservoir containing at least a first primer configured to specifically hybridize to a first end of at least one reference sequence, wherein the reference sequence has at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, chr5-180756063-180768074, chr6-170921836-170922549, chr7-39837560-63231088, chr7-128296352-128298474, chr8-143133-150475, chr9-49679-49771, chrY-26424506-27537936, or chr6-132951-145064; the at least one portion is present in at least a first minimum number of copies in the genome; and at least one copy of the at least one portion is present on each of at least a second minimum number of chromosomes., and a second primer configured to specifically hybridize to a sequence complementary to a second end of at least one reference sequence;
  • a detector configured to provide a first indication relating to an amount of the amplified sequence of interest and a second indication relating to an amount of the amplified reference sequence; and
  • a controller configured to quantify the amplified sequence of interest relative to the amplified reference sequence, based at least in part on the first indication and the second indication; and determine a copy number of the sequence of interest from the relative quantified amplified sequence of interest.
  • Nucleic acid amplifiers are known to the person of ordinary skill in the art. Generally, nucleic acid amplifiers use one or more primers and one or more chemical or enzymatic agents to copy a template nucleic acid sequence, such as a sequence of interest or a reference sequence. Such copying can be cycled multiple times to yield relatively large amounts of the sequence of interest and the reference sequence. Desirably, the nucleic acid amplifier is configured to amplify the sequence of interest and the reference sequence simultaneously and in parallel, e.g., by adding different sets of primers, one specific to the sequence of interest and the other specific to the reference sequence, to otherwise identical reaction solutions, such as in different wells of a multi-well plate.
  • The system also comprises a reagent reservoir. Generally, the reagent reservoir contains materials required for the amplification reaction to occur, such as primers, chemical or enzymatic agents, free nucleotides incorporable into copies of template sequences, etc. The reagent reservoir may also contain one or more probes or other compounds comprising detectable moieties. Any of these materials may be stored separately and/or two or more thereof may be combined for storage in the reagent reservoir. These materials are generally in aqueous solution and can be introduced to reaction solution(s) by techniques known to the person of ordinary skill in the art. Such introduction can occur once or multiple times before, during, or after an amplification process. For example, some reagent(s) may be added once per amplification cycle.
  • In one embodiment, the reagent reservoir containing at least a first primer configured to specifically hybridize to a first end of the at least one reference sequence, wherein the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:1-31, such as SEQ ID NO:1-13, and a second primer configured to specifically hybridize to a sequence complementary to a second end of the at least one reference sequence.
  • The reference sequence, the determination of a sequence identity percentage, and SEQ ID NO:1-38 are described elsewhere herein.
  • The system also comprises a detector. Generally, the detector may be configured to detect a probe for the sequence of interest, the reference sequence, or both. Upon detection, the detector may perform various signal processing and/or analysis operations to provide a first indication relating to an amount of the amplified sequence of interest and a second indication relating to an amount of the amplified reference sequence.
  • The system also comprises a controller. The controller may be configured to quantify the amplified sequence of interest relative to the amplified reference sequence, based at least in part on the first indication and the second indication; and determine a copy number of the sequence of interest from the relative quantified amplified sequence of interest. It may store the determined copy number in a memory, display it to a user, write it to a computer-readable file, or the like.
  • In a further embodiment, the controller may be configured to diagnose the subject as having a cancer-related biomarker, based on the sequence of interest being associated with the cancer and the copy number being indicative of the cancer.
  • Although the nucleic acid amplifier, the reagent reservoir, the detector, and the controller have been described separately above, any two or more thereof may be components of a single apparatus.
  • In certain embodiments, the disclosure provides:
  • 1. A method, comprising:amplifying a nucleic acid sequence of interest in a sample comprising genomic DNA of a subject;amplifying a reference sequence in the sample, wherein the reference sequence has at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, chr5-180756063-180768074, chr6-170921836-170922549, chr7-39837560-63231088, chr7-128296352-128298474, chr8-143133-150475, chr9-49679-49771, chrY-26424506-27537936, or chr6-132951-145064; the at least one portion is present in at least a first minimum number of copies in the genome; and at least one copy of the at least one portion is present on each of at least a second minimum number of chromosomes;quantifying the amplified sequence of interest relative to the amplified reference sequence; and determining a copy number of the sequence of interest from the relative quantified amplified sequence of interest.
  • 2. In the method, the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NOs: 1-31.
  • 3. In the method, the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NO:1-13.
  • 4. In the method, the sample can include tissue suspected of being cancer tissue.
  • 5. In the method, the sample has been subjected to formalin fixing and paraffin embedding (FFPE) prior to amplifying the sequence of interest and amplifying the reference sequence.
  • 6. The method can also include: diagnosing the subject as having a cancer-related biomarker, based on the sequence of interest being associated with the cancer and the copy number being indicative of the cancer.
  • 7. In the method, amplifying the sequence of interest and amplifying the reference sequence can be performed by TaqMan quantitative polymerase chain reaction (qPCR).
  • 8. A kit, comprising:a first probe which specifically hybridizes to at least a portion of at least one reference sequence having at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, chr5-180756063-180768074, chr6-170921836-170922549, chr7-39837560-63231088, chr7-128296352-128298474, chr8-143133-150475, chr9-49679-49771, chrY-26424506-27537936, or chr6-132951-145064; the at least one portion is present in at least a first minimum number of copies in the genome; and at least one copy of the at least one portion is present on each of at least a second minimum number of chromosomes
  • 9. In the kit, the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NO:1-31.
  • 10. In the kit, the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NO:1-13.
  • 11. In the kit, the first probe can include a nucleic acid sequence configured to specifically hybridize to at least the portion of the at least one reference sequence, a fluorescent reporter at a first end of the nucleic acid sequence, and a fluorescent quencher at a second end of the nucleic acid sequence.
  • 12. The kit can further include: a first primer configured to specifically hybridize to a first end of the at least one reference sequence, and a second primer configured to specifically hybridize to a sequence complementary to a second end of the at least one reference sequence.
  • 13. The kit can further include: a second probe which specifically hybridizes to at least a portion of at least one nucleic acid sequence of interest.
  • 14. The kit can further include: a third primer configured to specifically hybridize to a first end of the at least one nucleic acid sequence of interest, and a fourth primer configured to specifically hybridize to a sequence complementary to a second end of the at least one nucleic acid sequence of interest.
  • 15. A composition that includes: a first probe which specifically hybridizes to at least a portion of at least one reference sequence having at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, chr5-180756063-180768074, chr6-170921836-170922549, chr7-39837560-63231088, chr7-128296352-128298474, chr8-143133-150475, chr9-49679-49771, chrY-26424506-27537936, or chr6-132951-145064; the at least one portion is present in at least a first minimum number of copies in the genome; and at least one copy of the at least one portion is present on each of at least a second minimum number of chromosomes.
  • 16. In the composition, the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NO:1-31.
  • 17. In the composition, the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NO:1-13.
  • 18. In the composition, the first probe can include a nucleic acid sequence configured to specifically hybridize to at least the portion of the at least one reference sequence, a fluorescent reporter at a first end of the nucleic acid sequence, and a fluorescent quencher at a second end of the nucleic acid sequence.
  • 19. The composition can further include: a first primer configured to specifically hybridize to a first end of the at least one reference sequence, and a second primer configured to specifically hybridize to a sequence complementary to a second end of the at least one reference sequence.
  • 20. The composition can further include: a second probe which specifically hybridizes to at least a portion of at least one nucleic acid sequence of interest.
  • 21. The composition can further include: a third primer configured to specifically hybridize to a first end of the at least one nucleic acid sequence of interest, and a fourth primer configured to specifically hybridize to a sequence complementary to a second end of the at least one nucleic acid sequence of interest.
  • 22. A system that includes: a nucleic acid amplifier configured to amplify a nucleic acid sequence of interest in a sample comprising genomic DNA of a subject and amplify a reference sequence in the sample, a reagent reservoir containing at least a first primer configured to specifically hybridize to a first end of the at least one reference sequence, wherein the reference sequence has at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chrl-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, chr5-180756063-180768074, chr6-170921836-170922549, chr7-39837560-63231088, chr7-128296352-128298474, chr8-143133-150475, chr9-49679-49771, chrY-26424506-27537936, or chr6-132951-145064; the at least one portion is present in at least a first minimum number of copies in the genome; and at least one copy of the at least one portion is present on each of at least a second minimum number of chromosomes; , and a second primer configured to specifically hybridize to a sequence complementary to a second end of the at least one reference sequence; a detector configured to provide a first indication relating to an amount of the amplified sequence of interest and a second indication relating to an amount of the amplified reference sequence; and a controller configured to quantify the amplified sequence of interest relative to the amplified reference sequence, based at least in part on the first indication and the second indication; and determine a copy number of the sequence of interest from the relative quantified amplified sequence of interest.
  • 23. In the system, the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NO:1-31.
  • 24. In the system, the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NO:1-13.
  • 25. In the system, the sample can include tissue suspected of being cancer tissue.
  • 26. In the system, the sample has been subjected to formalin fixing and paraffin embedding (FFPE).
  • 27. In the system, the controller is further configured to indicate the subject as having a cancer-related biomarker, based on the sequence of interest being associated with the cancer and the copy number being indicative of the cancer.
  • 28. In the system, the nucleic acid amplifier is configured to amplify the sequence of interest and amplify the reference sequence by TaqMan quantitative polymerase chain reaction (qPCR).
  • 29. A method that includes quantifying a nucleic acid sequence of interest in a sample comprising genomic DNA of a subject relative to a reference sequence in the sample, wherein the reference sequence has at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, chr5-180756063-180768074, chr6-170921836-170922549, chr7-39837560-63231088, chr7-128296352-128298474, chr8-143133-150475, chr9-49679-49771, chrY-26424506-27537936, or chr6-132951-145064; the at least one portion is present in at least a first minimum number of copies in the genome; and at least one copy of the at least one portion is present on each of at least a second minimum number of chromosomes; and determining a copy number of the sequence of interest from the relative quantified nucleic acid sequence of interest.
  • 30. In the method, the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NO:1-38.
  • 31. In the method, the reference sequence can have at least 80% sequence identity to at least one of SEQ ID NO:1-13.
  • 32. In the method, the sample includes tissue suspected of being cancer tissue.
  • 33. In the method, the sample has been subjected to formalin fixing and paraffin embedding (FFPE) prior to amplifying the sequence of interest and amplifying the reference sequence.
  • 34. The method can further include: diagnosing the subject as having a cancer-related biomarker, based on the sequence of interest being associated with the cancer and the copy number being indicative of the cancer.
  • The following examples are included to demonstrate particular embodiments of the disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the disclosure, and thus can be considered to constitute particular modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the disclosure.
    • EXAMPLE 1
  • SEQ ID NO:1-13 were identified by a two-stage process. First, a bioinformatics algorithm was used to identify candidate targets in the genome that met certain criteria associated with substantially normal copy number, even in cancer cells subjected to FFPE. Generally, sequences suspected of being relatively resistant to copy number abnormalities in cancer cells and/or cells subjected to FFPE were used to query publicly-available human genomic databases, and only those sequences returning multiple hits were considered as candidate targets for further testing.
  • The first stage identified SEQ ID NO:1-31. SEQ ID NO:2-8 and 10-13 are located in the genome at the loci given supra. SEQ ID NO:14-31 are located in the genome at least at the following loci:
  • SEQ ID NO:14, chr10 38753941 . . . 38753964 . . . 38754039 chr11.11250s.
  • SEQ ID NO:15, chr10 38753848 . . . 38753866 . . . 38753912 chr11.11350s.
  • SEQ ID NO:16, chr10 38753856 . . . 38753896 . . . 38753934 chr1.5850s.
  • SEQ ID NO:17, chr10 38753715 . . . 38753794 . . . 38753862 chr1.5950s.
  • SEQ ID NO:18, chr10 38753145 . . . 38753206 . . . 38753248 chr16.2650s.
  • SEQ ID NO:19, chr10 38753377 . . . 38753408 . . . 38753457 chr16.2850s.
  • SEQ ID NO:20, chr10 38753232 . . . 38753257 . . . 38753351 chr20.2650s.
  • SEQ ID NO:21, chr10 38753326 . . . 38753360 . . . 38753411 chr20.2750s.
  • SEQ ID NO:22, chr10 38753413 . . . 38753454 . . . 38753513 chr20.2850s.
  • SEQ ID NO:23, chr11 123673 . . . 123696 . . . 123739 chr20.3850s.
  • SEQ ID NO:24, chr10 38750797 . . . 38750847 . . . 38750889 chr3.150s.
  • SEQ ID NO:25, chr10 38741930 . . . 38741975 . . . 38742018 chr3.1550s.
  • SEQ ID NO:26, chr10 38742246 . . . 38742274 . . . 38742312 chr3.1850s.
  • SEQ ID NO:27, chr10 38746651 . . . 38746676 . . . 38746733 chr3.6250s.
  • SEQ ID NO:28, chr10 38753090 . . . 38753126 . . . 38753234 chr5.2550s.
  • SEQ ID NO:29, chr10 38753486 . . . 38753535 . . . 38753587 chr5.2950s.
  • SEQ ID NO:30, chr10 38753797 . . . 38753835 . . . 38753885 chr5.3250s.
  • SEQ ID NO:31, chr10 38753907 . . . 3/8753935 . . . 38753971 chr5.3350s.
  • Twenty-three larger
    regions to which the
    candidate sequences
    mapped were as Starting Ending
    follows: Region Chromosome position position
    1 chr1  121790 133586
    2 chr1  329448 341534
    3 chr1  648129 660266
    4 chr1  222643865 228172047
    5 chr1  243203764 243215874
    6 chr10 38741930 38753964
    7 chr11 114010 126106
    8 chr16 90239446 90251554
    9 chr19 183944 196032
    10 chr2  114323560 114323652
    11 chr2  243064480 243071940
    12 chr20 62921559 62933673
    13 chr3  197950387 197962431
    14 chr4  119557144 120325498
    15 chr4  165196360 165199636
    16 chr5  180756063 180768074
    17 chr6  170921836 170922549
    18 chr7  39837560 63231088
    19 chr7  128296352 128298474
    20 chr8  143133 150475
    21 chr9  49679 49771
    22 chrY  26424506 27537936
    23 chr6  132951 145064
  • (As the person of ordinary skill in the art is aware, as of this writing, the resistance of a sequence to copy number abnormalities in cancer cells and/or cells subjected to FFPE cannot be predicted with sufficient accuracy from sequence data alone. Further testing, such as that described below, is required to identify sequences suitable for use as a multicopy reference assay).
  • Numerous qPCR, TaqMan reference assays were designed using the candidate targets and tested on cancer samples alongside a qPCR, TaqMan target of interest (TOI) assay. The assays mapped to the target regions many-fold:
  • number of number of
    id hits chromosomes
    chr11.11250s.1 16 11
    chr11.11350s.1 17 12
    chr1.5850s.1 17 11
    chr1.5950s.1 15 11
    chr16.2650s.1 15 11
    chr16.2850s.1 15 11
    chr16.3250s.1 16 11
    chr16.3350s.1 16 11
    chr20.2650s.1 16 11
    chr20.2750s.1 16 11
    chr20.2850s.1 16 11
    chr20.3250s.1 17 12
    chr20.3350s.1 16 11
    chr20.3850s.1 17 11
    chr2.3250s.1 15 11
    chr3.150s.1 15 12
    chr3.1550s.1 16 11
    chr3.1850s.1 23 11
    chr3.6250s.1 18 13
    chr5.2550s.1 17 12
    chr5.2850s.1 15 11
    chr5.2950s.1 19 13
    chr5.3250s.1 17 12
    chr5.3350s.1 16 11
  • After initial testing, two targets provided results suggestive of substantially normal copy number, even in cancer cells subjected to FFPE, and were selected for a final round of testing on an expanded panel of samples.
  • The final round of testing evaluated the performance of these two de novo qPCR multicopy reference assays, a conventional qPCR single copy reference assay (RNaseP) and five qPCR TOI assays for the IRS2 gene. The qPCR assays all used as template genomic DNA extracted from 35 colorectal normal tissue samples subjected to FFPE. All assays were performed in duplicate, with the reference assay and target of interest assay run in separate wells to generate accurate Cq values.
  • The first multicopy reference assay, corresponding to SEQ ID NO:1-8, used a first set comprising forward primer, reverse primer, and probe sequence. The second multicopy reference assay, corresponding to SEQ ID NO:9-13, used a second set comprising forward primer, reverse primer, and probe sequence.
  • The expectation was that a result of 2 copies for the IRS2 gene should be determined for normal samples, if a test generated accurate results. A snapshot summary of the results is provided in FIGS. 1A-3B for each of the three reference assays: RNaseP (FIGS. 1A-1B), SEQ ID NO:1-8 (FIGS. 2A-2B), and SEQ ID NO:9-13 (FIGS. 3A-3B). In each figure, the copy number is plotted on the y-axis and the 35 samples in duplicate times the five different IRS2 TOI assays are plotted on the x-axis. Each figure contains 350 data points.
  • The results depended not only on the reference assay used, but also the IRS2 TOI assay used. The two multicopy reference assays performed well, along with the first 3 IRS2 TOI assays. In each figure, subfigure A has decimal point calculated copy number, and subfigure B has rounded copy number.
  • All of the compositions, methods, and/or systems disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this disclosure have been described in terms of particular embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions, methods, and/or systems and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the disclosure. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the disclosure as defined by the appended claims.

Claims (20)

What is claimed is:
1. A method, comprising:
amplifying a nucleic acid sequence of interest in a sample comprising genomic DNA of a subject;
amplifying a reference sequence in the sample, wherein the reference sequence has at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs,
wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, chr5-180756063-180768074, chr6-170921836-170922549, chr7-39837560-63231088, chr7-128296352-128298474, chr8-143133-150475, chr9-49679-49771, chrY-26424506-27537936, or chr6-132951-145064;
the at least one portion is present in at least a first minimum number of copies in the genome; and
at least one copy of the at least one portion is present on each of at least a second minimum number of chromosomes;
quantifying the amplified sequence of interest relative to the amplified reference sequence; and
determining a copy number of the sequence of interest from the relative quantified amplified sequence of interest.
2. The method of claim 1, wherein the reference sequence has at least 80% sequence identity to at least one of SEQ ID NOs: 1-31.
3. The method of claim 1, wherein the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:1-13.
4. The method of claim 1, wherein the sample comprises tissue suspected of being cancer tissue.
5. The method of claim 4, wherein the sample has been subjected to formalin fixing and paraffin embedding (FFPE) prior to amplifying the sequence of interest and amplifying the reference sequence.
6. The method of claim 4, further comprising:
diagnosing the subject as having a cancer-related biomarker, based on the sequence of interest being associated with the cancer and the copy number being indicative of the cancer.
7. The method of claim 1, wherein amplifying the sequence of interest and amplifying the reference sequence are performed by TaqMan quantitative polymerase chain reaction (qPCR).
8. A composition, comprising:
a first probe which specifically hybridizes to at least a portion of at least one reference sequence having at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, chr5-180756063-180768074, chr6-170921836-170922549, chr7-39837560-63231088, chr7-128296352-128298474, chr8-143133-150475, chr9-49679-49771, chrY-26424506-27537936, or chr6-132951-145064;
the at least one portion is present in at least a first minimum number of copies in the genome; and
at least one copy of the at least one portion is present on each of at least a second minimum number of chromosomes.
9. The composition of claim 8, wherein the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:1-31.
10. The composition of claim 8, wherein the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:1-13.
11. The composition of claim 8, wherein the first probe comprises a nucleic acid sequence configured to specifically hybridize to at least the portion of the at least one reference sequence, a fluorescent reporter at a first end of the nucleic acid sequence, and a fluorescent quencher at a second end of the nucleic acid sequence.
12. The composition of claim 8, further comprising:
a first primer configured to specifically hybridize to a first end of the at least one reference sequence, and
a second primer configured to specifically hybridize to a sequence complementary to a second end of the at least one reference sequence.
13. The composition of claim 8, further comprising:
a second probe which specifically hybridizes to at least a portion of at least one nucleic acid sequence of interest.
14. The composition of claim 13, further comprising:
a third primer configured to specifically hybridize to a first end of the at least one nucleic acid sequence of interest, and
a fourth primer configured to specifically hybridize to a sequence complementary to a second end of the at least one nucleic acid sequence of interest.
15. A system, comprising:
a nucleic acid amplifier configured to amplify a nucleic acid sequence of interest in a sample comprising genomic DNA of a subject and amplify a reference sequence in the sample,
a reagent reservoir containing at least a first primer configured to specifically hybridize to a first end of the at least one reference sequence, wherein the reference sequence has at least 80% sequence identity to at least one portion of genomic DNA comprising from about 60 to about 150 base pairs, wherein the at least one portion is present in chr1-121790-133586, chr1-329448-341534, chr1-648129-660266, chr1-222643865-228172047, chr1-243203764-243215874, chr10-38741930-38753964, chr11-114010-126106, chr16-90239446-90251554, chr19-183944-196032, chr2-114323560-114323652, chr2-243064480-243071940, chr20-62921559-62933673, chr3-197950387-197962431, chr4-119557144-120325498, chr4-165196360-165199636, chr5-180756063-180768074, chr6-170921836-170922549, chr7-39837560-63231088, chr7-128296352-128298474, chr8-143133-150475, chr9-49679-49771, chrY-26424506-27537936, or chr6-132951-145064; the at least one portion is present in at least a first minimum number of copies in the genome; and at least one copy of the at least one portion is present on each of at least a second minimum number of chromosomes; , and a second primer configured to specifically hybridize to a sequence complementary to a second end of the at least one reference sequence;
a detector configured to provide a first indication relating to an amount of the amplified sequence of interest and a second indication relating to an amount of the amplified reference sequence; and
a controller configured to quantify the amplified sequence of interest relative to the amplified reference sequence, based at least in part on the first indication and the second indication; and determine a copy number of the sequence of interest from the relative quantified amplified sequence of interest.
16. The system of claim 15, wherein the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:1-31.
17. The system of claim 16, wherein the reference sequence has at least 80% sequence identity to at least one of SEQ ID NO:1-13.
18. The system of claim 17, wherein the sample comprises tissue suspected of being cancer tissue.
19. The system of claim 18, wherein the sample has been subjected to formalin fixing and paraffin embedding (FFPE).
20. The system of claim 19, wherein the controller is further configured to indicate the subject as having a cancer-related biomarker, based on the sequence of interest being associated with the cancer and the copy number being indicative of the cancer.
US17/301,976 2014-03-21 2021-04-20 Multi-copy reference assay Abandoned US20210254181A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US17/301,976 US20210254181A1 (en) 2014-03-21 2021-04-20 Multi-copy reference assay
US18/635,799 US20240263247A1 (en) 2014-03-21 2024-04-15 Multi-copy reference assay

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461968609P 2014-03-21 2014-03-21
PCT/US2015/021853 WO2015143385A1 (en) 2014-03-21 2015-03-20 Multi-copy reference assay
US201615128076A 2016-09-21 2016-09-21
US17/301,976 US20210254181A1 (en) 2014-03-21 2021-04-20 Multi-copy reference assay

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US15/128,076 Division US11008621B2 (en) 2014-03-21 2015-03-20 Multi-copy reference assay
PCT/US2015/021853 Division WO2015143385A1 (en) 2014-03-21 2015-03-20 Multi-copy reference assay

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/635,799 Division US20240263247A1 (en) 2014-03-21 2024-04-15 Multi-copy reference assay

Publications (1)

Publication Number Publication Date
US20210254181A1 true US20210254181A1 (en) 2021-08-19

Family

ID=52997523

Family Applications (3)

Application Number Title Priority Date Filing Date
US15/128,076 Active 2035-04-02 US11008621B2 (en) 2014-03-21 2015-03-20 Multi-copy reference assay
US17/301,976 Abandoned US20210254181A1 (en) 2014-03-21 2021-04-20 Multi-copy reference assay
US18/635,799 Pending US20240263247A1 (en) 2014-03-21 2024-04-15 Multi-copy reference assay

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/128,076 Active 2035-04-02 US11008621B2 (en) 2014-03-21 2015-03-20 Multi-copy reference assay

Family Applications After (1)

Application Number Title Priority Date Filing Date
US18/635,799 Pending US20240263247A1 (en) 2014-03-21 2024-04-15 Multi-copy reference assay

Country Status (4)

Country Link
US (3) US11008621B2 (en)
EP (2) EP3546594B1 (en)
ES (2) ES2843848T3 (en)
WO (1) WO2015143385A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015143385A1 (en) 2014-03-21 2015-09-24 Life Technologies Corporation Multi-copy reference assay
JP6685138B2 (en) * 2016-01-27 2020-04-22 シスメックス株式会社 Quality control method for nucleic acid amplification, quality control reagent and reagent kit therefor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399364B1 (en) * 1998-03-19 2002-06-04 Amersham Biosciences Uk Limited Sequencing by hybridization
US20040181048A1 (en) * 2000-10-24 2004-09-16 Wang David G Identification and mapping of single nucleotide polymorphisms in the human genome
US20140162894A1 (en) * 2012-09-27 2014-06-12 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
US20140274734A1 (en) * 2013-03-14 2014-09-18 Qiagen Sciences, Llc Dna quality controls
US9040243B2 (en) * 2010-09-23 2015-05-26 Qiagen Gmbh Method for detecting and/or quantifying human DNA

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005300688B2 (en) * 2004-11-03 2012-02-02 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
JP2009519710A (en) 2005-12-16 2009-05-21 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Functional arrays for high-throughput characterization of gene expression regulatory elements
US9689031B2 (en) 2007-07-14 2017-06-27 Ionian Technologies, Inc. Nicking and extension amplification reaction for the exponential amplification of nucleic acids
WO2015143385A1 (en) 2014-03-21 2015-09-24 Life Technologies Corporation Multi-copy reference assay

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399364B1 (en) * 1998-03-19 2002-06-04 Amersham Biosciences Uk Limited Sequencing by hybridization
US20040181048A1 (en) * 2000-10-24 2004-09-16 Wang David G Identification and mapping of single nucleotide polymorphisms in the human genome
US9040243B2 (en) * 2010-09-23 2015-05-26 Qiagen Gmbh Method for detecting and/or quantifying human DNA
US20140162894A1 (en) * 2012-09-27 2014-06-12 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
US20140274734A1 (en) * 2013-03-14 2014-09-18 Qiagen Sciences, Llc Dna quality controls

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neid (J Biological Chemistry, 2004, Vol 279, pp 3941-3948) *

Also Published As

Publication number Publication date
EP3546594A2 (en) 2019-10-02
ES2843848T3 (en) 2021-07-20
EP3119906B1 (en) 2019-01-16
US20170096711A1 (en) 2017-04-06
US20240263247A1 (en) 2024-08-08
ES2719122T3 (en) 2019-07-08
EP3119906A1 (en) 2017-01-25
EP3546594B1 (en) 2020-12-23
WO2015143385A1 (en) 2015-09-24
EP3546594A3 (en) 2019-12-04
US11008621B2 (en) 2021-05-18

Similar Documents

Publication Publication Date Title
US20210355537A1 (en) Compositions and methods for identification of a duplicate sequencing read
Alonso et al. Real-time PCR designs to estimate nuclear and mitochondrial DNA copy number in forensic and ancient DNA studies
US10102337B2 (en) Digital measurements from targeted sequencing
US20240263247A1 (en) Multi-copy reference assay
US20180195118A1 (en) Systems and methods for detection of genomic copy number changes
EP2147120B1 (en) Improved lysis and reverse transcription for mrna quantification
JP2015165828A (en) Multiplex amplification of polynucleotides
JP2009502137A (en) Method for rapid identification and quantification of nucleic acid variants
US10544447B2 (en) DNA quality assessments using repetitive sequences
JP6021230B2 (en) Method for quantifying human DNA using internal controls
JP2016526390A (en) Method for performing polymerase chain reaction and related uses
JP2013111081A (en) Quantitative pcr-based method to predict the efficiency of target enrichment for next-generation sequencing using repetitive dna element (line/sine) as negative control
Fujimoto et al. Optimal small-molecular reference RNA for RT-qPCR-based body fluid identification
CN109923215B (en) Detection of sequence variants
US20240084363A1 (en) Method for quantifying and/or detecting human male dna
US20100297622A1 (en) Method for high-throughput gene expression profile analysis
US20180291443A1 (en) Library Quantitation And Qualification
US20110269137A1 (en) Rapid and efficient assay to assess the sequence and size of 3' ends of polynucleotides
KR102156699B1 (en) Composition for determining Soeumin
JP2020516274A (en) Library quantification and qualification
Cawthon A novel PCR method directly quantifies sequence features that block primer extension
JP2010000003A (en) Method for detecting copy number of target nucleic acid sequence

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

AS Assignment

Owner name: LIFE TECHNOLOGIES CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MERRILL, DAVID;BRZOSKA, PIUS;LI, ZHENG;AND OTHERS;SIGNING DATES FROM 20170713 TO 20170825;REEL/FRAME:056689/0448

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION